Atara Biotherapeutics Company Profile (NASDAQ:ATRA)

About Atara Biotherapeutics

Atara Biotherapeutics logoAtara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. Its T-cell product candidates include Epstein Barr Virus-cytotoxic T lymphocytes (EBV-CTL), which is in Phase II clinical trials for malignancies associated with EBV; cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1. Its molecularly targeted product candidates include STM 434, which is in Phase I clinical trial of STM 434 for ovarian cancer and other solid tumors; ATA 777, a fully human antibody targeting Activin A; ATA M43, a fully human anti-Actin-related protein 2-A (ActR2A)/2B monoclonal antibody; STM 217; ActR2B5, and ATA 842, a humanized antibody targeting myostatin.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ATRA
  • CUSIP:
Key Metrics:
  • Previous Close: $14.80
  • 50 Day Moving Average: $14.87
  • 200 Day Moving Average: $17.54
  • 52-Week Range: $12.45 - $25.73
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.52
  • P/E Growth: 0.00
  • Market Cap: $427.13M
  • Outstanding Shares: 28,860,000
  • Beta: 1.43
Profitability:
  • Return on Equity: -27.80%
  • Return on Assets: -26.80%
Debt:
  • Current Ratio: 20.63%
  • Quick Ratio: 20.63%
Additional Links:
Companies Related to Atara Biotherapeutics:

Analyst Ratings

Consensus Ratings for Atara Biotherapeutics (NASDAQ:ATRA) (?)
Ratings Breakdown: 2 Sell Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $27.33 (84.68% upside)

Analysts' Ratings History for Atara Biotherapeutics (NASDAQ:ATRA)
Show:
DateFirmActionRatingPrice TargetDetails
1/18/2017Canaccord GenuitySet Price TargetBuy$47.00View Rating Details
12/12/2016Jefferies Group LLCSet Price TargetBuy$23.00View Rating Details
9/15/2016Goldman Sachs Group, Inc. (The)DowngradeNeutral -> Sell$23.00 -> $16.00View Rating Details
8/19/2016Citigroup Inc.Boost Price TargetSell$8.00 -> $10.00View Rating Details
7/9/2016JMP SecuritiesReiterated RatingBuyView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$40.00 -> $34.00View Rating Details
12/15/2015William BlairReiterated RatingBuyView Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Atara Biotherapeutics (NASDAQ:ATRA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2017        
11/4/2016Q3 2016($0.78)($0.88)ViewN/AView Earnings Details
5/5/2016Q1($0.55)($0.58)ViewN/AView Earnings Details
11/5/2015($0.53)($0.43)ViewN/AView Earnings Details
8/6/2015Q215($0.44)($0.43)ViewN/AView Earnings Details
2/26/2015($0.35)($0.67)ViewN/AView Earnings Details
11/12/2014Q314($4.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Atara Biotherapeutics (NASDAQ:ATRA)
Current Year EPS Consensus Estimate: $-3.10 EPS
Next Year EPS Consensus Estimate: $-4.21 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.68)($0.68)($0.68)
Q2 20161($0.65)($0.65)($0.65)
Q3 20162($0.80)($0.77)($0.79)
Q4 20162($0.90)($0.90)($0.90)
Q1 20171($0.87)($0.87)($0.87)
Q2 20171($0.88)($0.88)($0.88)
Q3 20171($0.89)($0.89)($0.89)
Q4 20171($0.90)($0.90)($0.90)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Atara Biotherapeutics (NASDAQ:ATRA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Atara Biotherapeutics (NASDAQ:ATRA)
Insider Ownership Percentage: 16.10%
Institutional Ownership Percentage: 77.48%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/21/2017John McgrathCFOSell9,000$15.14$136,260.00View SEC Filing  
2/16/2017Carol Giltner GallagherDirectorSell1,183$16.10$19,046.30View SEC Filing  
2/16/2017Isaac E CiechanoverCEOSell4,800$15.56$74,688.00View SEC Filing  
2/16/2017Mitchall G. ClarkEVPSell3,059$15.96$48,821.64View SEC Filing  
2/15/2017Christopher HaqqEVPSell7,604$15.49$117,785.96View SEC Filing  
2/10/2017Gad SofferEVPSell6,274$15.47$97,058.78View SEC Filing  
2/9/2017Christopher HaqqEVPSell13,975$15.46$216,053.50View SEC Filing  
2/3/2017Isaac E CiechanoverCEOSell4,800$13.66$65,568.00View SEC Filing  
1/18/2017Isaac E CiechanoverCEOSell6,000$14.24$85,440.00View SEC Filing  
1/17/2017Christopher HaqqEVPSell6,000$14.27$85,620.00View SEC Filing  
1/6/2017Isaac E CiechanoverCEOSell8,400$16.89$141,876.00View SEC Filing  
12/23/2016Isaac E CiechanoverCEOSell4,800$15.22$73,056.00View SEC Filing  
12/15/2016Christopher HaqqInsiderSell6,000$15.40$92,400.00View SEC Filing  
12/7/2016Isaac E CiechanoverCEOSell7,200$17.93$129,096.00View SEC Filing  
11/23/2016Isaac E CiechanoverCEOSell12,000$18.34$220,080.00View SEC Filing  
11/22/2016Isaac E CiechanoverCEOSell8,400$18.21$152,964.00View SEC Filing  
11/16/2016Carol Giltner GallagherDirectorSell1,184$19.35$22,910.40View SEC Filing  
11/16/2016Gad SofferCOOSell16,718$20.00$334,360.00View SEC Filing  
11/16/2016Mitchall G ClarkInsiderSell2,995$19.53$58,492.35View SEC Filing  
11/14/2016Gad SofferCOOSell9,582$20.55$196,910.10View SEC Filing  
11/11/2016John McgrathCFOSell5,000$19.84$99,200.00View SEC Filing  
10/27/2016Isaac E CiechanoverCEOSell4,800$13.81$66,288.00View SEC Filing  
10/14/2016Isaac E CiechanoverCEOSell4,800$15.96$76,608.00View SEC Filing  
10/12/2016John McgrathCFOSell5,000$17.47$87,350.00View SEC Filing  
9/28/2016Isaac E CiechanoverCEOSell12,000$20.87$250,440.00View SEC Filing  
9/16/2016Isaac E CiechanoverCEOSell7,200$19.36$139,392.00View SEC Filing  
8/23/2016Isaac E CiechanoverCEOSell9,600$22.33$214,368.00View SEC Filing  
8/16/2016Gad SofferCOOSell5,356$22.41$120,027.96View SEC Filing  
8/15/2016Christopher HaqqInsiderSell1,346$22.32$30,042.72View SEC Filing  
7/21/2016Isaac E CiechanoverCEOSell9,600$22.11$212,256.00View SEC Filing  
7/8/2016Isaac E CiechanoverCEOSell9,600$22.88$219,648.00View SEC Filing  
6/24/2016Isaac E CiechanoverCEOSell9,600$21.26$204,096.00View SEC Filing  
6/8/2016Isaac E CiechanoverCEOSell12,000$20.53$246,360.00View SEC Filing  
6/7/2016Isaac E CiechanoverCEOSell7,200$20.36$146,592.00View SEC Filing  
5/26/2016Isaac E CiechanoverCEOSell7,200$17.69$127,368.00View SEC Filing  
5/18/2016Carol Giltner GallagherDirectorSell1,184$15.96$18,896.64View SEC Filing  
5/17/2016Gad SofferCOOSell5,427$15.91$86,343.57View SEC Filing  
5/16/2016John McgrathCFOSell5,395$15.77$85,079.15View SEC Filing  
5/16/2016Mitchall G ClarkInsiderSell4,153$15.15$62,917.95View SEC Filing  
4/26/2016Isaac E CiechanoverCEOSell1,300$20.12$26,156.00View SEC Filing  
4/12/2016Isaac E CiechanoverCEOSell13,210$20.40$269,484.00View SEC Filing  
4/1/2016Isaac E CiechanoverCEOSell1,190$20.03$23,835.70View SEC Filing  
3/17/2016Eric DobmeierDirectorBuy3,000$13.86$41,580.00View SEC Filing  
2/17/2016Carol Giltner GallagherDirectorSell1,183$16.30$19,282.90View SEC Filing  
2/17/2016Gad SofferCOOSell5,711$16.77$95,773.47View SEC Filing  
1/14/2016Isaac E CiechanoverCEOSell2,400$20.20$48,480.00View SEC Filing  
12/31/2015Isaac E CiechanoverCEOSell2,400$26.00$62,400.00View SEC Filing  
12/16/2015Eric DobmeierDirectorBuy2,500$22.00$55,000.00View SEC Filing  
12/15/2015Isaac E CiechanoverCEOSell2,400$22.46$53,904.00View SEC Filing  
12/4/2015Isaac E CiechanoverCEOSell4,000$37.45$149,800.00View SEC Filing  
11/30/2015John McgrathCFOSell6,000$40.00$240,000.00View SEC Filing  
11/24/2015Isaac E CiechanoverCEOSell4,800$35.03$168,144.00View SEC Filing  
11/17/2015Carol Giltner GallagherDirectorSell1,184$31.10$36,822.40View SEC Filing  
11/17/2015Gad SofferCOOSell7,586$31.22$236,834.92View SEC Filing  
10/22/2015Isaac E CiechanoverCEOSell3,200$25.85$82,720.00View SEC Filing  
10/7/2015Isaac E CiechanoverCEOSell4,000$33.08$132,320.00View SEC Filing  
9/24/2015Isaac E CiechanoverCEOSell5,200$42.99$223,548.00View SEC Filing  
9/11/2015Isaac E. CiechanoverCEOSell5,200$46.16$240,032.00View SEC Filing  
8/31/2015Christopher HaqqinsiderSell5,000$41.99$209,950.00View SEC Filing  
8/28/2015Isaac E CiechanoverCEOSell5,200$39.25$204,100.00View SEC Filing  
8/24/2015Carol Giltner GallagherDirectorSell17,622$42.34$746,115.48View SEC Filing  
8/19/2015Carol Giltner GallagherDirectorSell5,875$48.18$283,057.50View SEC Filing  
8/18/2015Carol Giltner GallagherDirectorSell5,764$49.38$284,626.32View SEC Filing  
8/18/2015Gad SofferCOOSell7,711$49.49$381,617.39View SEC Filing  
8/18/2015John McgrathCFOSell6,000$49.38$296,280.00View SEC Filing  
8/17/2015Gad SofferCOOSell8,778$50.00$438,900.00View SEC Filing  
8/17/2015Mitchall G ClarkInsiderSell7,829$46.19$361,621.51View SEC Filing  
7/17/2015Isaac E CiechanoverCEOSell5,200$60.71$315,692.00View SEC Filing  
7/15/2015Christopher HaqqInsiderSell2,500$62.94$157,350.00View SEC Filing  
7/1/2015Christopher HaqqInsiderSell2,500$51.68$129,200.00View SEC Filing  
7/1/2015Isaac E CiechanoverCEOSell5,200$50.42$262,184.00View SEC Filing  
6/18/2015Isaac E CiechanoverCEOSell5,200$54.72$284,544.00View SEC Filing  
6/15/2015Christopher HaqqInsiderSell7,500$46.42$348,150.00View SEC Filing  
6/15/2015John McgrathCFOSell10,000$50.00$500,000.00View SEC Filing  
6/5/2015Isaac E CiechanoverCEOSell6,400$42.91$274,624.00View SEC Filing  
6/1/2015Christopher HaqqInsiderSell2,500$41.47$103,675.00View SEC Filing  
5/29/2015John McgrathCFOSell10,000$40.00$400,000.00View SEC Filing  
5/22/2015Isaac E CiechanoverCEOSell4,000$37.56$150,240.00View SEC Filing  
4/23/2015Isaac E CiechanoverCEOSell5,200$61.36$319,072.00View SEC Filing  
3/10/2015Joel S MarcusDirectorBuy4,000$29.57$118,280.00View SEC Filing  
2/18/2015Carol Giltner GallagherDirectorBuy11,000$18.00$198,000.00View SEC Filing  
10/21/2014Domain Partners Viii, L.P.Major ShareholderBuy248,159$11.00$2,729,749.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Atara Biotherapeutics (NASDAQ:ATRA)
DateHeadline
marketexclusive.com logoInsider Trading Activity Atara Biotherapeutics, Inc. (NASDAQ:ATRA ... - Market Exclusive (NASDAQ:ATRA)
marketexclusive.com - February 23 at 3:44 PM
4-traders.com logoMnuchin says dollar strength reflects confidence in U.S. economy: WSJ (NASDAQ:ATRA)
www.4-traders.com - February 23 at 1:45 AM
4-traders.com logoInsider Trading Activity Atara Biotherapeutics, Inc. (NASDAQ:ATRA) – CFO Sold 9,000 shares of Stock (NASDAQ:ATRA)
www.4-traders.com - February 22 at 8:43 PM
News IconSell-side Consensus Sees Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Going Where Near-Term? - Aiken Advocate (NASDAQ:ATRA)
aikenadvocate.com - February 22 at 11:20 AM
News IconAtara Biotherapeutics Inc ATRA Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:ATRA)
www.bioportfolio.com - February 20 at 8:58 AM
seekingalpha.com logoTracking Seth Klarman's Baupost Group Holdings - Q4 2016 Update (NASDAQ:ATRA)
seekingalpha.com - February 16 at 8:35 AM
4-traders.com logoInsider Trading Activity Atara Biotherapeutics, Inc. (NASDAQ:ATRA) – EVP Sold 6,274 shares of Stock (NASDAQ:ATRA)
www.4-traders.com - February 14 at 4:23 PM
biz.yahoo.com logoATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:ATRA)
biz.yahoo.com - February 10 at 9:12 PM
biz.yahoo.com logoATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:ATRA)
biz.yahoo.com - February 8 at 3:34 PM
marketexclusive.com logoAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:ATRA)
marketexclusive.com - February 7 at 4:36 PM
News IconErratic Volume Stretches This Stock Mid-Session: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Davidson Register (NASDAQ:ATRA)
davidsonregister.com - February 6 at 3:44 PM
News IconReviewing Individual Broker Targets Of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - NewsDen (NASDAQ:ATRA)
newsden.net - February 4 at 1:51 AM
News IconIs Selling 52-Week Stock Like Atara Biotherapeutics Inc (ATRA) a Winning Strategy? (NASDAQ:ATRA)
randolphguide.com - February 1 at 2:00 AM
News IconEarnings Parade Rolls On, What Are Analysts Saying About Atara Biotherapeutics, Inc. (NASDAQ:ATRA)? - Wall Street Beacon (NASDAQ:ATRA)
wsbeacon.com - January 31 at 3:54 PM
News IconVolatility Watch on Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Gilbert Daily (NASDAQ:ATRA)
gilbertdaily.com - January 30 at 1:42 AM
News IconFollowing FCF Scores for Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - The Tribune (NASDAQ:ATRA)
lakecitytribune.com - January 27 at 4:51 PM
News IconEarnings in Full Force, Analysts Take Aim at Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Wall Street Beacon (NASDAQ:ATRA)
wsbeacon.com - January 24 at 4:11 PM
News IconEarnings According to Analysts for Atara Biotherapeutics, Inc. (NASDAQ:ATRA)? - Aiken Advocate (NASDAQ:ATRA)
aikenadvocate.com - January 24 at 4:11 PM
News IconVC Score In Focus for Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - The Tribune (NASDAQ:ATRA)
lakecitytribune.com - January 23 at 3:46 PM
4-traders.com logoInsider Trading Activity Atara Biotherapeutics Inc. (NASDAQ:ATRA) – CEO Sold 6,000 shares of Stock (NASDAQ:ATRA)
www.4-traders.com - January 20 at 3:35 AM
marketexclusive.com logoInsider Trading Activity Atara Biotherapeutics Inc. (NASDAQ:ATRA ... - Market Exclusive (NASDAQ:ATRA)
marketexclusive.com - January 19 at 9:49 PM
News IconAlanis Morissette Manager Admits to Stealing Nearly $5M From Singer (NASDAQ:ATRA)
baddgoddess.com - January 19 at 2:22 AM
News IconStock Getting Tripped Up In Session: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Wall Street Beacon (NASDAQ:ATRA)
wsbeacon.com - January 11 at 3:57 PM
News IconAtara Biotherapeutics Inc ATRA Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:ATRA)
www.bioportfolio.com - January 9 at 8:05 AM
finance.yahoo.com logoAtara Bio to Present at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:ATRA)
finance.yahoo.com - January 4 at 3:49 PM
globenewswire.com logoReimbursement Discussions with Health Technology Assessment Agencies Being Conducted in Parallel (NASDAQ:ATRA)
globenewswire.com - January 3 at 8:39 AM
einnews.com logoAtara Bio Concludes EMA Scientific Advice and Plans to Submit Conditional Marketing Authorization Application (MAA) in ... (NASDAQ:ATRA)
semiconductors.einnews.com - January 3 at 8:39 AM
publicnow.com logoAtara Bio Concludes EMA Scientific Advice and Plans to Submit Conditional Marketing Authorization Application (MAA) in Europe for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, for the Treatment of E (NASDAQ:ATRA)
www.publicnow.com - January 3 at 8:39 AM
News IconShares to Watch: Indicator Update on Atara Biotherapeutics Inc. (ATRA) - StockTalk Daily (NASDAQ:ATRA)
stocktalkdaily.com - December 22 at 2:50 AM
News IconUpdate on Valuation Formula's For Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Marion Business Daily (NASDAQ:ATRA)
marionbusinessdaily.com - December 20 at 8:32 AM
News IconStock Tracker: Looking at the Numbers for Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Marion Business Daily (NASDAQ:ATRA)
marionbusinessdaily.com - December 18 at 8:44 PM
News IconVC Score In Focus for Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - The Business Journal (NASDAQ:ATRA)
belmontbusinessjournal.com - December 18 at 1:47 AM
News IconTrading Focus: Checking ATR Levels for Atara Biotherapeutics Inc. (ATRA) - StockTalk Daily (NASDAQ:ATRA)
stocktalkdaily.com - December 16 at 3:50 PM
News IconAtara Biotherapeutics Inc (ATRA): Are Hedge Funds Right About This Stock? (NASDAQ:ATRA)
feedproxy.google.com - December 14 at 6:25 AM
us.rd.yahoo.com logo8:01 am Atara Biotherapeutics reaches agreement with FDA on design of phase 3 Trials for Allogeneic Epstein-Barr Virus -Specific Cytotoxic T Lymphocytes to 'support potential approval' in two separate indications (NASDAQ:ATRA)
us.rd.yahoo.com - December 12 at 8:52 PM
News IconStock Watch: FCF Score Check on Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - The Business Journal (NASDAQ:ATRA)
belmontbusinessjournal.com - December 12 at 8:23 AM
streetinsider.com logoATARA Biotherapeutics (ATRA) Says Agreement Reached with FDA on Design of Phase 3 Trials for ATA 129 - StreetInsider.com (NASDAQ:ATRA)
www.streetinsider.com - December 12 at 8:23 AM
finance.yahoo.com logoAtara Bio Reaches Agreement with FDA on Design of Phase 3 Trials for its Lead Anti-Cancer Immunotherapy Program, Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, to Support Potential Approval in Two Se (NASDAQ:ATRA)
finance.yahoo.com - December 12 at 8:23 AM
News IconInvestor Monitor: Narrowing in on Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - The Business Journal (NASDAQ:ATRA)
belmontbusinessjournal.com - December 6 at 8:56 PM
streetinsider.com logoATARA Biotherapeutics (ATRA) Announces Encouraging Data from CMV-CTL Phase 2 in CMV-Specific CTLs (NASDAQ:ATRA)
www.streetinsider.com - December 5 at 4:33 PM
streetinsider.com logoATARA Biotherapeutics (ATRA) Announces Encouraging Data from CMV-CTL Phase 2 in CMV-Specific CTLs - StreetInsider.com (NASDAQ:ATRA)
www.streetinsider.com - December 5 at 8:33 AM
finance.yahoo.com logo1:29 am Atara Biotherapeutics reports results from ongoing Phase 2 Trial of Allogeneic Cytomegalovirus; Response Rate and 6-month Overall Survival > 70% (NASDAQ:ATRA)
finance.yahoo.com - December 5 at 8:32 AM
finance.yahoo.com logoAtara Bio Announces Results from Ongoing Phase 2 Trial of Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic … (NASDAQ:ATRA)
finance.yahoo.com - December 4 at 8:48 AM
News IconStock Update: Focusing on Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - The Business Journal (NASDAQ:ATRA)
belmontbusinessjournal.com - December 3 at 3:35 PM
finance.yahoo.com logoAtara Bio Announces Results from Ongoing Phase 2 Trial of Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) at the American Society of Hematology (ASH) Annual Meeting 2016 (NASDAQ:ATRA)
finance.yahoo.com - December 3 at 3:35 PM
News IconInvestor Watch: Checking in on Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Marion Business Daily (NASDAQ:ATRA)
marionbusinessdaily.com - December 2 at 9:08 PM
News IconFollowing the Numbers on Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - The Business Journal (NASDAQ:ATRA)
belmontbusinessjournal.com - November 30 at 3:41 PM
capitalcube.com logoAtara Biotherapeutics, Inc. :ATRA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 (NASDAQ:ATRA)
www.capitalcube.com - November 29 at 5:03 PM
News IconInside the Numbers: Checking on Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Wall Street Lion (NASDAQ:ATRA)
wslnews.com - November 21 at 8:30 AM
News IconInvestor Watch on Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Marion Business Daily (NASDAQ:ATRA)
marionbusinessdaily.com - November 18 at 1:05 PM

Social

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

Where is Atara Biotherapeutics' stock going? Where will Atara Biotherapeutics' stock price be in 2017?

6 analysts have issued 12-month price targets for Atara Biotherapeutics' stock. Their forecasts range from $10.00 to $47.00. On average, they anticipate Atara Biotherapeutics' share price to reach $27.33 in the next year.

When will Atara Biotherapeutics announce their earnings?

Atara Biotherapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.

Who owns Atara Biotherapeutics stock?

Atara Biotherapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Baupost Group LLC MA (18.57%), FMR LLC (9.64%), Arrowpoint Asset Management LLC (5.41%), State Street Corp (2.08%), Artal Group S.A. (1.73%) and Alyeska Investment Group L.P. (1.41%). Company insiders that own Atara Biotherapeutics stock include Carol Giltner Gallagher, Christopher Haqq, Eric Dobmeier, Gad Soffer, Isaac E Ciechanover, Joel S Marcus, John Mcgrath and Mitchall G Clark.

Who sold Atara Biotherapeutics stock? Who is selling Atara Biotherapeutics stock?

Atara Biotherapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and RTW Investments LP. Company insiders that have sold Atara Biotherapeutics stock in the last year include Carol Giltner Gallagher, Christopher Haqq, Gad Soffer, Isaac E Ciechanover, John Mcgrath and Mitchall G Clark.

Who bought Atara Biotherapeutics stock? Who is buying Atara Biotherapeutics stock?

Atara Biotherapeutics' stock was acquired by a variety of institutional investors in the last quarter, including 12 West Capital Management LP, Artal Group S.A., Arrowpoint Asset Management LLC, State Street Corp, EcoR1 Capital LLC, Elkfork Partners LLC, Dimensional Fund Advisors LP and Alyeska Investment Group L.P.. Company insiders that have bought Atara Biotherapeutics stock in the last two years include Eric Dobmeier and Joel S Marcus.

How do I buy Atara Biotherapeutics stock?

Shares of Atara Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Atara Biotherapeutics stock cost?

One share of Atara Biotherapeutics stock can currently be purchased for approximately $14.80.

Atara Biotherapeutics (NASDAQ:ATRA) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Earnings History Chart

Earnings by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Dividend History Chart

Dividend Payments by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Last Updated on 2/23/2017 by MarketBeat.com Staff